abmart-banner
Global R&D Pipeline
My Favorite
Hot Targets:
Home>AbMart>

Global R&D Pipeline

NaPi-2b
Back
Total number of drugs
25
Phase II and later clinical stages
12%
Involving companies
23
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
DrugDrug Name EnDrug TypeTreatment FieldMechanism of ActionOriginatorDeveloperIndicationHighest Development StageHighest Development Stage (China)Approved Countries/RegionsApproved TimeApproved Time (China)Special ReviewADC TypeADC LinkerADC PayloadADC DARDrug NameAntibody TypeADC Linking SiteOperation
LM-001(LaNova Medicines)LM-001(LaNova Medicines)Antibody drug conjugate (ADC) ADCNeoplasms Endocrinology and Metabolic Disease Respiratory Diseases Urogenital DiseasesSodium-dependent phosphate transport protein 2B inhibitorsLaNova Medicines Ltd.PreclinicalPreclinicalLM-001(LaNova Medicines)
detail  >
NaPi-2b inhibitors(Kyowa Kirin)NaPi-2b inhibitors(Kyowa Kirin)Small molecule drugEndocrinology and Metabolic DiseaseSodium-dependent phosphate transport protein 2B inhibitorsKyowa Kirin Co., Ltd.Kyowa Kirin Co., Ltd.PreclinicalNaPi-2b inhibitors(Kyowa Kirin)
detail  >
NaPi2b-PL2202NaPi2b-PL2202Antibody drug conjugate (ADC) ADCNeoplasms Endocrinology and Metabolic Disease Respiratory Diseases Urogenital DiseasesSodium-dependent phosphate transport protein 2B inhibitors DNA topoisomerase I inhibitorsADC Therapeutics SAADC Therapeutics SAPreclinicalVal-AlaExatecan 依喜替康6NaPi2b-PL2202
detail  >
XMT-1592XMT-1592Antibody drug conjugate (ADC) ADCNeoplasms Respiratory DiseasesSodium-dependent phosphate transport protein 2B inhibitors Tubulin inhibitorsMersana Therapeutics, Inc.Mersana Therapeutics, Inc.PreclinicalProtease cleavable linker 酶裂解AF-HPA6XMT-1592IgG1 - ndasparagine 天冬酰胺
detail  >
ZW-220ZW-220Antibody drug conjugate (ADC) ADCNeoplasms Endocrinology and Metabolic Disease Respiratory Diseases Urogenital DiseasesSodium-dependent phosphate transport protein 2B inhibitors DNA topoisomerase I inhibitorsZymeworks BC, Inc.Zymeworks, Inc.PreclinicalMC-GGFGZD065194-8ZW-220IgG1 - ndcysteinyl 半胱氨酸
detail  >
UpifitamabUpifitamabMonoclonal antibodySodium-dependent phosphate transport protein 2B inhibitorsMersana Therapeutics, Inc.Mersana Therapeutics, Inc.DiscoveryUpifitamab
detail  >
Lifastuzumab vedotinLifastuzumab vedotinAntibody drug conjugate (ADC) ADCNeoplasms Digestive System Disorders Endocrinology and Metabolic Disease Urogenital Diseases Respiratory DiseasesSodium-dependent phosphate transport protein 2B inhibitors Tubulin inhibitorsGenentech, Inc.Phase 2LifastuzumabMc-Val-Cit-PABC-PNPMMAE 甲基澳瑞他汀E3-4Lifastuzumab vedotinIgG1 - kappacysteinyl 半胱氨酸
detail  >
99mTc-Rebmab20099mTc-Rebmab200Radiolabeled antibody Diagnostic radiopharmaceuticalsNeoplasms Endocrinology and Metabolic Disease Urogenital DiseasesSodium-dependent phosphate transport protein 2B inhibitorsRecepta Biopharma SAPreclinical99m Tc99mTc-Rebmab200
detail  >
RebmAb200RebmAb200Monoclonal antibodyNeoplasmsSodium-dependent phosphate transport protein 2B inhibitorsRecepta Biopharma SAPreclinicalRebmAb200
detail  >
ASP-3325ASP-3325Small molecule drugEndocrinology and Metabolic Disease Urogenital DiseasesSodium-dependent phosphate transport protein 2B inhibitorsAstellas Pharma, Inc.Phase 1ASP-3325
detail  >
Total 25 data
1
2
3